The Role of 68Gallium PSMA-11 in Enhancing Diagnosis of Primary and Metastatic Prostate Cancer

2019 ◽  
Author(s):  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer

The role of WNT5A in tumor and tumor surrounding tissue in primary and metastatic prostate cancer

2020 ◽  
Author(s):  
W Kisel ◽  
S Conrad ◽  
S Füssel ◽  
U Sommer ◽  
GB Baretton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Surrounding Tissue

Personalizing Therapy for Metastatic Prostate Cancer: The Role of Solid and Liquid Tumor Biopsies

2017 ◽  
pp. 358-369 ◽  
Author(s):  
Terence W. Friedlander ◽  
Colin C. Pritchard ◽  
Himisha Beltran
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Tumor Tissue ◽  
Neuroendocrine Differentiation ◽  
Metastatic Tumor ◽  
Metastatic Lesion ◽  
Phenotypic Changes ◽  
Tumor Biopsies ◽  
Bioinformatic Approach

Although biopsies of metastatic prostate cancer are rarely undertaken in the clinical setting, there is increasing interest in developing personalized approaches to therapy by taking into account the genetic and phenotypic changes in an individual tumor. Indeed, analysis of metastatic prostate tumors can predict sensitivity to agents that inhibit DNA repair and resistance to novel hormonal agents, such as abiraterone and enzalutamide, and identify phenotypic changes, such as neuroendocrine differentiation, that have important clinical implications. Although obtaining metastatic tumor tissue is necessary for this genomic and molecular profiling, knowing when to biopsy, selecting the appropriate metastatic lesion, and interpreting the results are major challenges facing clinicians today. In this article, we discuss the rationale for obtaining metastatic tumor tissue, review the bioinformatic approach to analyzing these specimens, discuss the timing and approach to solid and liquid tumor biopsies, review the challenges associated with obtaining and acting on clinically relevant results, and discuss opportunities for the future.

scholarly journals The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis

2018 ◽  
Vol 38 (1) ◽  
Author(s):  
Yi Wang ◽  
Zhiqiang Qin ◽  
Yamin Wang ◽  
Chen Chen ◽  
Yichun Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Gleason Score ◽  
Metastatic Prostate Cancer ◽  
Meta Analysis ◽  
Local Therapy ◽  
Quality Data ◽  
N Stage ◽  
High Level

The recommended therapy by EAU guidelines for metastatic prostate cancer (mPCa) is androgen deprivation therapy (ADT) with or without chemotherapy. The role of radical prostatectomy (RP) in the treatment of mPCa is still controversial. Hence, a meta-analysis was conducted by comprehensively searching the databases PubMed, EMBASE and Web of Science for the relevant studies published before September 1st, 2017. Our results successfully shed light on the relationship that RP for mPCa was associated with decreased cancer-specific mortality (CSM) (pooled HR = 0.41, 95%CI = 0.36–0.47) and enhanced overall survival (OS) (pooled HR = 0.49, 95%CI = 0.44–0.55). Subsequent stratified analysis demonstrated that no matter how RP compared with no local therapy (NLT) or radiation therapy (RT), it was linked to a lower CSM (pooled HR = 0.36, 95%CI = 0.30–0.43 and pooled HR = 0.56, 95%CI 0.43–0.73, respectively) and a higher OS (pooled HR = 0.49, 95%CI = 0.44–0.56 and pooled HR = 0.46, 95%CI 0.33–0.65, separately). When comparing different levels of Gleason score, M-stage or N-stage, our results indicated that high level of Gleason score, M-stage or N-stage was associated with increased CSM. In summary, the outcomes of the present meta-analysis demonstrated that RP for mPCa was correlated with decreased CSM and enhanced OS in eligible patients of involved studies. In addition, patients with less aggressive tumors and good general health seemed to benefit the most. Moreover, no matter compared with NLT or RT, RP showed significant superiority in OS or CSM. Upcoming prospective randomized controlled trials were warranted to provide more high-quality data.

Abstract B11: Using three-dimensional (3-D) culture systems to delineate the role of RANKL in metastatic prostate cancer

2013 ◽  
Author(s):  
Shabnam Ziaee ◽  
Shirly Sieh ◽  
Chia-Yi Chu ◽  
Ruoxiang Wang ◽  
Dietmar Hutmacher ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Metastatic Prostate Cancer ◽  
Three Dimensional ◽  
Culture Systems

scholarly journals Androgen receptor antagonists for prostate cancer therapy

2014 ◽  
Vol 21 (4) ◽  
pp. T105-T118 ◽  
Author(s):  
Christine Helsen ◽  
Thomas Van den Broeck ◽  
Arnout Voet ◽  
Stefan Prekovic ◽  
Hendrik Van Poppel ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Androgen Receptor ◽  
Metastatic Prostate Cancer ◽  
Castration Resistant ◽  
Androgen Action ◽  
Conflicting Evidence ◽  
Prostate Cancer Therapy ◽  
Androgen Receptor Antagonists

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.

Role of radical prostatectomy in metastatic prostate cancer: A review

2017 ◽  
Vol 35 (4) ◽  
pp. 125-134 ◽  
Author(s):  
Michael J. Metcalfe ◽  
Marc C. Smaldone ◽  
Daniel W. Lin ◽  
Ana M. Aparicio ◽  
Brian F. Chapin
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Metastatic Prostate Cancer
Sign in / Sign up

Export Citation Format

Share Document